Announced Tue, 21 Jul · 08:41 IST
Glenmark gets US FDA nod to expand RYALTRIS use in kids aged 6-12
GLENMARK · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-1.6%1-day move
₹2242.20
prior close
₹2245.80
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.3-0.7-0.7-0.7-1.6-1.8-1.8-1.9——————
Up moveDown movePending
AI summary
Glenmark's RYALTRIS nasal spray, already approved for adults and kids 12 and above, can now be used in children aged 6 to under 12 for seasonal allergic rhinitis in the US. Approval is backed by a Phase 3 study of 446 children showing improved nasal symptoms over 14 days. RYALTRIS is now sold in 56 countries. Glenmark took over direct US commercialization of RYALTRIS from April 2026.
Likely market impact
Broadens the addressable US patient base for RYALTRIS and supports Glenmark's direct US respiratory push. Positive for revenue growth.